Research Efforts Are Underway for Follicular Lymphoma

Steven I. Park, MD, discusses the unique design of the SYMPHONY-1 trial, the importance of enrolling patients to the phase 3 portion of the study, and why tazemetostat in combination with lenalidomide and rituximab could represent an effective and tolerable therapeutic option for frail or older patients with relapsed/refractory follicular lymphoma.

Julie M. Vose, MD, MBA, discusses the investigation of tazemetostat vs placebo when given in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma in the phase 3 SYMPHONY-1 study.

Although relapsed/refractory follicular lymphoma remains a difficult- to-treat disease, the emergence of anti-CD20 monoclonal antibodies in recent years has signaled progress, including the 2019 FDA approval of rituximab plus lenalidomide.

Steven Park, MD, discusses the mechanism of action of tazemetostat and the rationale for the phase 3 SYMPHONY-1 trial in patients with relapsed follicular lymphoma.

Jennifer Effie Amengual, MD, discusses considerations for community oncologists looking to refer patients with relapsed/refractory follicular lymphoma (FL) to the ongoing second-line, phase 3 SYMPHONY-1 trial (NCT04224493).

Jennifer Effie Amengual, MD, discusses unmet needs in FL that SYMPHONY-1 aims to address; the potential benefits of tazemetostat plus lenalidomide and rituximab in patients who are refractory to rituximab or who relapse within 24 months of their initial therapy; and where this regimen may fit into the relapsed/refractory FL treatment paradigm alongside investigative CAR T-cell therapies.